VEGFR2

Class

Selective VEGFR2 tyrosine kinase inhibitor

Pathway

Blocks VEGF/VEGFR2 autophosphorylation and downstream ERK/STAT3/PI3K-AKT signaling, inhibiting tumor angiogenesis

VEGFR2 (vascular endothelial growth factor receptor 2) is a receptor located on the surface of endothelial cells, the cells lining blood vessels. When its ligand, VEGF, binds, the receptor activates internal signaling cascades that drive new blood vessel formation, a process called angiogenesis. Solid tumors depend on this process to secure oxygen and nutrients for continued growth, and they often produce excess VEGF to stimulate it. Blocking VEGFR2 signaling interrupts this supply line, limiting tumor vascularization and, in principle, slowing growth and spread. This mechanism is relevant across many solid tumor types where angiogenesis supports disease progression. Two general approaches exist: antibodies that intercept the receptor before it can engage its ligand, and small-molecule inhibitors that enter the cell and block the receptor's internal enzymatic activity directly. Both converge on the same downstream effect—reduced endothelial cell proliferation and vessel formation—but differ in how selectively they act and how they are administered. Because VEGFR2 signaling also maintains normal vascular and kidney function, inhibiting it carries recognized physiological trade-offs alongside its intended anti-tumor effect, which is why this mechanism is generally studied and used within broader combination strategies rather than as an isolated approach.